Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aphrodite study of amrubicin + durvalumab in recurrent small cell lung cancer
jRCT2061220036Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amrubicin and durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoint: 1-year survival rate. Started Oct 2022; status: completed.
02
Drugs
amrubicindurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2061220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220036.